A Prospective, Randomised, Open-label Phase IIb Clinical Trial Assessing the Effect of Pegylated Interferon Alfa-2a (Pegasys)180 microg Once Weekly for 48 Weeks in Addition to an Ongoing Nucelos(t)Ide Based Treatment on Quantitative HBsAg Levels in Patients With Chronic HBeAg-negative Hepatitis B.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 21 Sep 2017
At a glance
- Drugs Peginterferon alfa-2a (Primary) ; Nucleosides; Nucleotides
- Indications Hepatitis B
- Focus Therapeutic Use
- Acronyms PADD-ON
- 21 Sep 2017 This trial has been completed in Germany according to European clinical trials database record.
- 21 Aug 2017 Planned primary completion date changed from 1 Jul 2017 to 1 Aug 2017.
- 07 Mar 2017 Status changed from recruiting to active, no longer recruiting.